Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole versus placebo for auditory verbal hallucinations in young people with borderline personality disorder
ACTRN12616001192471Phase 3Completed
- Sponsor
- Orygen
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in borderline personality disorder (BPD) comparing Aripiprazole with Placebo (2 arms). Primary endpoint: Change in severity of auditory verbal hallucinations at 39 weeks. Started Oct 2016; status: completed.
02
Drugs
aripiprazole
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on ACTRN12616001192471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001192471.